Loading...

B Michael Silber, PhD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentBioengineering
AddressLocation Required
Varies CA 00000
Phone650-269-8044
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California San Francisco, Graduate SchoolPhD1981Pharmaceutical Chemistry and Pharmacology
    University of California San FranciscoPostdoctoral Fellowship1977Clinical Pharmacy
    University of Southern CaliforniaDoctor of Pharmacy1976Clinical Pharmacy

    Collapse Overview 
    Collapse Overview
    Dr. Silber is Professor, Department of Bioengineering and Therapeutic Sciences, University of California San Francisco (UCSF), Schools of Medicine and Pharmacy. Until recently, he was also Professor of Neurology and Chief of Drug Discovery R & D at UCSF’s Institute for Neurodegenerative Diseases, which he led. Current research interests include discovering, developing and launching innovative breakthrough therapeutic and diagnostic products for diseases with high unmet medical need, including pain, inflammation, cancer, eye, neurodegenerative, and infectious diseases.

    He is also President and CEO of Reiley Pharmaceuticals focused on breakthrough products for pain, cancer and infectious disease, President and CEO of MacRegen focused on breakthrough drugs for age-related macular degeneration, Senior Advisor at Clinakos, Novakos, and Neurokos, and Scientific Advisory Board member of NextBio/Illumina and Optivia. He was previously President and CEO of Elmedtech, Senior VP of R & D at Roche, VP of R & D and CSO at ALZA/J & J, Director of R & D at Pfizer, Senior Director of R & D at Cetus, and Director of R & D at Lederle Labs.

    Dr. Silber has contributed to the discovery, preclinical and clinical development, registration, or commercial success of 23 FDA approved drugs (12 of which have been block busters) and drug devices and diagnostics in many disease areas. He is the author of more than 215 peer-reviewed publications, book chapters, patents, abstracts, and invited presentations.

    He has discovered and developed medicines and breakthrough technologies in pain, neurological and neurodegenerative (e.g., Alzheimer’s, Parkinson’s, ALS, MS, FTD, TBI, CTE, CJD), psychotherapeutic (e.g., depression, schizophrenia, ADHD), cancer, eye disease, obesity, diabetes, infectious, lipid, inflammatory, cardiovascular, skin, and respiratory diseases.

    Hobbies include mentoring graduate and health profession students, tennis, skiing, photography, and travel.


    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Giles K, Berry DB, Condello C, Hawley RC, Gallardo-Godoy A, Bryant C, Oehler A, Elepano M, Bhardwaj S, Patel S, Silber BM, Guan S, DeArmond SJ, Renslo AR, Prusiner SB. Different 2-Aminothiazole Therapeutics Produce Distinct Patterns of Scrapie Prion Neuropathology in Mouse Brains. J Pharmacol Exp Ther. 2015 Oct; 355(1):2-12. PMID: 26224882; PMCID: PMC4576665 [Available on 10/01/16].
      View in: PubMed, PubMed Central
    2. Silber BM, Gever JR, Rao S, Li Z, Renslo AR, Widjaja K, Wong C, Giles K, Freyman Y, Elepano M, Irwin JJ, Jacobson MP, Prusiner SB. Novel compounds lowering the cellular isoform of the human prion protein in cultured human cells. Bioorg Med Chem. 2014 Mar 15; 22(6):1960-72. PMID: 24530226; PMCID: PMC3984052.
      View in: PubMed, PubMed Central
    3. Silber, B.M.OMICS in Neuroscience, Giovanni Coppola Editor. From Small Molecule Leads to Clinical Candidates in Neurological Diseases. 2014; 291-314.
      View Publication
    4. Silber BM, Gever JR, Li Z, Gallardo-Godoy A, Renslo AR, Widjaja K, Irwin JJ, Rao S, Jacobson MP, Ghaemmaghami S, Prusiner SB. Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells. Bioorg Med Chem. 2013 Dec 15; 21(24):7999-8012. PMID: 24183589; PMCID: PMC3984054.
      View in: PubMed, PubMed Central
    5. Lu D, Giles K, Li Z, Rao S, Dolghih E, Gever JR, Geva M, Elepano ML, Oehler A, Bryant C, Renslo AR, Jacobson MP, Dearmond SJ, Silber BM, Prusiner SB. Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice. J Pharmacol Exp Ther. 2013 Nov; 347(2):325-38. PMID: 23965382; PMCID: PMC3807058.
      View in: PubMed, PubMed Central
    6. Li Z, Rao S, Gever JR, Widjaja K, Prusiner SB, Silber BM. Optimization of Arylamides as Novel, Potent and Brain-penetrant Antiprion Lead Compounds. ACS Med Chem Lett. 2013 Jul 11; 4(7):647-650. PMID: 23977416.
      View in: PubMed
    7. Li Z, Gever J, Rao S, Widjaja K, Prusiner SB, Silber BM. Discovery and Preliminary SAR of Arylpiperazines as Novel, Brainpenetrant Antiprion Compounds. ACS Med Chem Lett. 2013 Apr 11; 4(4):397-401. PMID: 23847718.
      View in: PubMed
    8. Li Z, Silber BM, Rao S, Gever JR, Bryant C, Gallardo-Godoy A, Dolghih E, Widjaja K, Elepano M, Jacobson MP, Prusiner SB, Renslo AR. 2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease. ChemMedChem. 2013 May; 8(5):847-57. PMID: 23509039; PMCID: PMC3984044.
      View in: PubMed, PubMed Central
    9. Silber BM, Rao S, Fife KL, Gallardo-Godoy A, Renslo AR, Dalvie DK, Giles K, Freyman Y, Elepano M, Gever JR, Li Z, Jacobson MP, Huang Y, Benet LZ, Prusiner SB. Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice. Pharm Res. 2013 Apr; 30(4):932-50. PMID: 23417511; PMCID: PMC3640342.
      View in: PubMed, PubMed Central
    10. Thompson MJ, Louth JC, Ferrara S, Jackson MP, Sorrell FJ, Cochrane EJ, Gever J, Baxendale S, Silber BM, Roehl HH, Chen B. Discovery of 6-substituted indole-3-glyoxylamides as lead antiprion agents with enhanced cell line activity, improved microsomal stability and low toxicity. Eur J Med Chem. 2011 Sep; 46(9):4125-32. PMID: 21726921.
      View in: PubMed
    11. Gallardo-Godoy A, Gever J, Fife KL, Silber BM, Prusiner SB, Renslo AR. 2-Aminothiazoles as therapeutic leads for prion diseases. J Med Chem. 2011 Feb 24; 54(4):1010-21. PMID: 21247166; PMCID: PMC3041857.
      View in: PubMed, PubMed Central
    12. Silber BM. Driving drug discovery: the fundamental role of academic labs. Sci Transl Med. 2010 May 05; 2(30):30cm16. PMID: 20445199.
      View in: PubMed
    13. Arrow K, Auerbach A, Bertko J, Brownlee S, Casalino LP, Cooper J, Crosson FJ, Enthoven A, Falcone E, Feldman RC, Fuchs VR, Garber AM, Gold MR, Goldman D, Hadfield GK, Hall MA, Horwitz RI, Hooven M, Jacobson PD, Jost TS, Kotlikoff LJ, Levin J, Levine S, Levy R, Linscott K, Luft HS, Mashal R, McFadden D, Mechanic D, Meltzer D, Newhouse JP, Noll RG, Pietzsch JB, Pizzo P, Reischauer RD, Rosenbaum S, Sage W, Schaeffer LD, Sheen E, Silber BM, Skinner J, Shortell SM, Thier SO, Tunis S, Wulsin L, Yock P, Nun GB, Bryan S, Luxenburg O, van de Ven WP. Toward a 21st-century health care system: recommendations for health care reform. Ann Intern Med. 2009 Apr 07; 150(7):493-5. PMID: 19258550.
      View in: PubMed
    14. Silber, B Michael.Pharmacogenetics, Edited by Werner Kalow, Urs Meyer and Rachel Tyndale. Pharmacogenomics, Biomarkers and the Promise of Personalized Medicine. 2001; 11-31.
    15. Silber, B.M.in Biomarkers and Surrogate Endpoints: Clinical Research and Applications, edited by G. Downing. The Importance of Biomarkers in Drug Discovery and Development-Focus on Alzheimer's Disease. 2000.
    16. McElroy S, Sachse C, Brockmoller J, Richmond J, Lira M, Friedman D, Roots I, Silber BM, Milos PM. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS PharmSci. 2000; 2(4):E33. PMID: 11741249; PMCID: PMC2751283.
      View in: PubMed, PubMed Central
    17. Silber, B.M.Proceedings of the First International Pharmacogenomics and Pharmacogenetics Forum, edited by T. Noguchi and Y. Fujita. Use of Genetic Variation-Response Outcome Relationships in Drug Development and Discovery. 1999.
    18. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 1997 Oct; 283(1):46-58. PMID: 9336307.
      View in: PubMed
    19. Potchoiba MJ, Tensfeldt TG, Nocerini MR, Silber BM. A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography. J Pharmacol Exp Ther. 1995 Feb; 272(2):953-62. PMID: 7853213.
      View in: PubMed
    20. Inskeep PB, Connolly AG, Cole MJ, Luther EW, Biehl ML, Marzetta CA, Savoy YE, Silber BM. Pharmacokinetics of tiqueside (beta-tigogenin cellobioside) in dogs, rats, rabbits, and monkeys. J Pharm Sci. 1995 Jan; 84(1):12-4. PMID: 7714734.
      View in: PubMed
    21. Cheung WK, Silber BM, Yacobi A. Pharmacokinetic principles in the design of immediate-release components in sustained-release formulations with zero-order release characteristics. J Pharm Sci. 1991 Feb; 80(2):142-8. PMID: 2051317.
      View in: PubMed
    22. Cheung WK, Greene DS, Kuye O, Smith MP, Holder A, Fernandez P, Houston A, Faulkner RD, Silber BM. Pharmacokinetics of YTR830H in healthy human subjects. J Chemother. 1989 Jul; 1(4 Suppl):505-6. PMID: 16312505.
      View in: PubMed
    23. Cheung WK, Greene DS, Kuye O, Shin K, Tonelli AP, Houston A, Hibberd M, Faulkner RD, Silber BM. Pharmacokinetics of YTR830H and piperacillin after intravenous coadministration. J Chemother. 1989 Jul; 1(4 Suppl):507-8. PMID: 16312506.
      View in: PubMed
    24. Faulkner RD, Sia LL, Barone JS, Forbes SJ, Silber BM. Bioequivalency of oral suspension formulations of cefixime. Biopharm Drug Dispos. 1989 Mar-Apr; 10(2):205-11. PMID: 2706319.
      View in: PubMed
    25. Cheung, W.K., Sia, L.L., Hibberd, M., Pearse, S., Woodward, D.L., Desjardins, R.E., Bernstein, J., Yacobi, A., and Silber, B.M.Pharmacokinetics of Nilvadipine After Multiple Dosing to Steady-State. Drug Dev. Indus. Pharm. . 1989; (15):51-63.
    26. Cheung WK, Sia LL, Woodward DL, Graveline JF, Desjardins RE, Yacobi A, Silber BM. Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipine. J Clin Pharmacol. 1988 Nov; 28(11):1001-7. PMID: 3243913.
      View in: PubMed
    27. Cheung WK, Stravinski SS, Engel SI, Sia LL, Yacobi A, Silber BM. Pharmacokinetic evaluation of a sustained-release formulation of trihexyphenidyl in healthy volunteers. J Pharm Sci. 1988 Sep; 77(9):748-50. PMID: 3225767.
      View in: PubMed
    28. Faulkner RD, Fernandez P, Lawrence G, Sia LL, Falkowski AJ, Weiss AI, Yacobi A, Silber BM. Absolute bioavailability of cefixime in man. J Clin Pharmacol. 1988 Aug; 28(8):700-6. PMID: 3216036.
      View in: PubMed
    29. Faulkner RD, Bohaychuk W, Lanc RA, Haynes JD, Desjardins RE, Yacobi A, Silber BM. Pharmacokinetics of cefixime in the young and elderly. J Antimicrob Chemother. 1988 Jun; 21(6):787-94. PMID: 3410802.
      View in: PubMed
    30. Bialer M, Wu WH, Faulkner RD, Silber BM, Yacobi A. In vitro protein binding interaction studies involving cefixime. Biopharm Drug Dispos. 1988 May-Jun; 9(3):315-20. PMID: 3395672.
      View in: PubMed
    31. Wu WH, Henderson BM, Lanc R, Garnes D, Yacobi A, Silber BM. Relationship between the pharmacokinetic and pharmacodynamic profile of nilvadipine in the dog. Drug Metab Dispos. 1988 Mar-Apr; 16(2):222-7. PMID: 2898337.
      View in: PubMed
    32. Faulkner RD, Bohaychuk W, Haynes JD, Desjardins RE, Yacobi A, Silber BM. The pharmacokinetics of cefixime in the fasted and fed state. Eur J Clin Pharmacol. 1988; 34(5):525-8. PMID: 3203716.
      View in: PubMed
    33. Cheung WK, Aiache M, Yacobi A, Silber BM. Changes in tissue concentrations of 14C-doxorubicin caused by mitoxantrone, mithramycin A and vinblastine in the rat. Res Commun Chem Pathol Pharmacol. 1988 Jan; 59(1):61-8. PMID: 2965402.
      View in: PubMed
    34. Cheung WK, Woodward DL, Shin K, Hibberd M, Pearse S, Desjardins RE, Yacobi A, Silber BM. Pharmacokinetics of nilvadipine after single oral doses in healthy volunteers. Int J Clin Pharmacol Res. 1988; 8(5):299-305. PMID: 3229870.
      View in: PubMed
    35. Faulkner, R.D., Sia, L.L., Look, Z.M., Barone, J.S., Forbes, St. J., Weiss, A.I., and Silber, B.M.Bioequivalency of Solid Oral Dosage Forms of Cefixime. Int. J. Pharmaceut. 1988; (43):53-58.
    36. Silber, B.M., Cheung, W.K., and Yacobi, A.Drug Absorption from Sustained Release Formulations, Edited by A. Yacobi and E. Halperin-Walega. Utilizing Pharmacokinetic Principles in the Design of Controlled or Sustained Release Formulations. 1988; 1-33.
    37. Falkowski AJ, Look ZM, Noguchi H, Silber BM. Determination of cefixime in biological samples by reversed-phase high-performance liquid chromatography. J Chromatogr. 1987 Nov 27; 422:145-52. PMID: 3437003.
      View in: PubMed
    38. McAteer JA, Hiltke MF, Silber BM, Faulkner RD. Liquid-chromatographic determination of five orally active cephalosporins--cefixime, cefaclor, cefadroxil, cephalexin, and cephradine--in human serum. Clin Chem. 1987 Oct; 33(10):1788-90. PMID: 3665031.
      View in: PubMed
    39. Faulkner RD, Yacobi A, Barone JS, Kaplan SA, Silber BM. Pharmacokinetic profile of cefixime in man. Pediatr Infect Dis J. 1987 Oct; 6(10):963-70. PMID: 3696837.
      View in: PubMed
    40. Faulkner RD, Bohaychuk W, Desjardins RE, Look ZM, Haynes JD, Weiss AI, Silber BM. Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state. J Clin Pharmacol. 1987 Oct; 27(10):807-12. PMID: 3429686.
      View in: PubMed
    41. Bialer M, Wu WH, Look ZM, Silber BM, Yacobi A. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding. Res Commun Chem Pathol Pharmacol. 1987 Apr; 56(1):21-32. PMID: 3589152.
      View in: PubMed
    42. Bialer M, Batra VK, Morrison JA, Silber BM, Look ZM, Yacobi A. Dose-dependent pharmacokinetics of a new oral cephalosporin, cefixime, in the dog. Pharm Res. 1987 Feb; 4(1):33-7. PMID: 3508527.
      View in: PubMed
    43. Cheung, W.K., Yacobi, A. and Silber, B.M.Pharmacokinetic Approach to the Rational Design of Controlled or Sustained Release Formulations. J. Control. Rel. 1987; 3(5):263-270.
    44. Silber, B.M., Bialer, M., and Yacobi, A.Sustained and Controlled Release Drug Delivery Systems, 2nd Edition, edited by J.R. Robinson and V.H. Lee. Pharmacokinetic-Pharmacodynamic Basis of Controlled Drug Delivery. 1987; 213-251.
    45. Tonelli, A.P., Nicolau, G., Lawter, J.R., Silber, B.M., Lanc, R.A., Lanzilotti, A.R., Dente, A.R., McWilliams, W.E., and Yacobi, A.Decapeptyl: Release from Microcapsules and Testosterone Suppression in the Dog, The Pharmacology and Toxicology of Proteins, pp. 337-349. 1987.
    46. Bialer M, Look ZM, Silber BM, Yacobi A. The relationship between drug input and mean residence time in the body. Biopharm Drug Dispos. 1986 Nov-Dec; 7(6):577-83. PMID: 3828487.
      View in: PubMed
    47. Lo MW, Pond SM, Effeney DJ, Silber BM, Riegelman S, Tozer TN. Nonlinear formation of propranolol metabolites in dogs after portacaval transpositions. J Pharmacokinet Biopharm. 1984 Aug; 12(4):401-12. PMID: 6527232.
      View in: PubMed
    48. Silber, B.M. and Holford, N.H.G.Pharmacokinetics: A Modern View, edited by L.Z. Benet and G. Levy. Stereoselective Disposition and Glucuronidation of Propranolol in Man. 1984; 478-481.
    49. Lo, M.W., Effeney, D.J., Pond, S.M., and Silber, B.M.Pharmacokinetics: A Modern View, edited by L.Z. Benet and G. Levy. The Use of the Portacaval Transposition Technique to Study Gastrointestinal and Hepatic Metabolism of Propranolol in the Dog. 1984; 474-477.
    50. Gupte SM, Bartels MJ, Kerr BM, Laganiere S, Silber BM, Nelson WL. Chemical aspects of propranolol metabolism. Synthesis and identification of 3-(4-hydroxy-1-naphthoxy)propane-1,2-diol as a metabolite of propranolol in the dog, in man and in the rat liver 9000g supernatant fraction. Res Commun Chem Pathol Pharmacol. 1983 Nov; 42(2):235-44. PMID: 6658188.
      View in: PubMed
    51. Silber BM, Holford NH, Riegelman S. Dose-dependent elimination of propranolol and its major metabolites in humans. J Pharm Sci. 1983 Jul; 72(7):725-32. PMID: 6886977.
      View in: PubMed
    52. Silber B, Holford NH, Riegelman S. Stereoselective disposition and glucuronidation of propranolol in humans. J Pharm Sci. 1982 Jun; 71(6):699-704. PMID: 7097538.
      View in: PubMed
    53. Lo MW, Effeney DJ, Pond SM, Silber BM, Riegelman S. Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition. J Pharmacol Exp Ther. 1982 May; 221(2):512-5. PMID: 7077541.
      View in: PubMed
    54. Effeney DJ, Pond SM, Lo MW, Silber BM, Riegelman S. A technique to study hepatic and intestinal drug metabolism separately in the dog. J Pharmacol Exp Ther. 1982 May; 221(2):507-11. PMID: 7077540.
      View in: PubMed
    55. Lo MW, Silber B, Riegelman S. An automated HPLC method for the assay of propranolol and its basic metabolites in plasma and urine. J Chromatogr Sci. 1982 Mar; 20(3):126-31. PMID: 7076780.
      View in: PubMed
    56. Silber B, Mico BA, Ortiz de Montellano PR, Dols DM, Riegelman S. In vivo effects of the cytochrome P-450 suicide substrate 2-isopropyl-4-pentenamide (allylisopropylacetamide) on the disposition and metabolic pattern of propranolol. J Pharmacol Exp Ther. 1981 Oct; 219(1):125-33. PMID: 7288600.
      View in: PubMed
    57. Silber B, Riegelman S. Stereospecific assay for (-)- and (+)-propranolol in human and dog plasma. J Pharmacol Exp Ther. 1980 Dec; 215(3):643-8. PMID: 7441523.
      View in: PubMed
    58. Silber B, Lo M, Riegelman S. The influence of heparin administration on the plasma protein binding and disposition of propranolol. Res Commun Chem Pathol Pharmacol. 1980 Mar; 27(3):419-29. PMID: 7384636.
      View in: PubMed
    59. Bernad PG, Silber B, Mathieu A. [Hepatic and renal toxicity of enflurane (author's transl)]. Anesth Analg (Paris). 1980; 37(7-8):427-8. PMID: 7425324.
      View in: PubMed
    60. Silber, B.M.Drug Level Monitoring, edited by W. Sadee and G.C.M. Beelen. Acetazolamide; Hydrochlorthiazide; Tetrahydrocannabinol. 1980; 117-119; 268-270; 447-453.
    61. Silber B, Sheiner LB, Powers JL, Winter ME, Sadée W. Spironolactone-associated digoxin radioimmunoassay interference. Clin Chem. 1979 Jan; 25(1):48-50. PMID: 761378.
      View in: PubMed
    B Michael's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (188) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (12) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    ↑